Qiagen Buys Xeragon for $8M to Bolster Oligo Business | GenomeWeb

NEW YORK, April 18 - Qiagen said today it has bought Xeragon for about $8 million as part of its goal of expanding its oligonucleotide business.

Qiagen paid for the deal by issuing 564,000 shares in exchange for all of the outstanding capital stock of Xeragon. Qiagen said it may issue an additional payment of up to $1.2 million in cash or stock if certain performance targets are met by next December.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.